White Paper
AI in cGMP Manufacturing
This white paper was developed by Project Farma experts dedicated to helping pharmaceutical and biotechnology manufacturers enhance operational performance within regulated environments. Joe O’Brien and Jim Rice bring extensive experience across manufacturing, automation, and quality systems, along with a deep understanding of the governance frameworks, data integrity requirements, and lifecycle controls essential for introducing new technologies into cGMP operations.
The insights presented in this paper outline key operational and regulatory considerations that organizations should evaluate when planning for the responsible adoption of artificial intelligence in manufacturing.
What Our Experts Share
- Where AI is beginning to show potential value in pharmaceutical manufacturing operations.
- Common operational challenges that create opportunities for improved data visibility and decision support.
- Regulatory and governance considerations teams should plan for before introducing AI capabilities.
- Data quality and context-of-use expectations that influence system reliability and performance.
- Risk-based approaches for introducing AI in a controlled, compliant manner.
.jpg?width=1545&height=2000&name=AI%20in%20GMP%20Manufacturing%20-%20Cover%20(2).jpg)


